Senores Pharmaceuticals (NSE:SENORES) EV-to-FCF: (As of Jul. 13, 2026)


NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
29 GF Score
Price ₹1,417.80
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Senores Pharmaceuticals's Enterprise Value is ₹65,702 Mil. Senores Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Senores Pharmaceuticals's EV-to-FCF for today is .

The historical rank and industry rank for Senores Pharmaceuticals's EV-to-FCF or its related term are showing as below:

NSE:SENORES' s EV-to-FCF Range Over the Past 10 Years
Min: -32.42   Med: 0   Max: 0
Current: -32.42

NSE:SENORES's EV-to-FCF is ranked worse than
100% of 562 companies
in the Drug Manufacturers industry
Industry Median: 20.955 vs NSE:SENORES: -32.42

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-13), Senores Pharmaceuticals's stock price is ₹1417.80. Senores Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹26.390. Therefore, Senores Pharmaceuticals's PE Ratio (TTM) for today is 53.72.


Senores Pharmaceuticals  (NSE:SENORES) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Senores Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1417.80/26.390
=53.72

Senores Pharmaceuticals's share price for today is ₹1417.80.
Senores Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹26.390.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Senores Pharmaceuticals EV-to-FCF Related Terms


Senores Pharmaceuticals EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals EV-to-FCF Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
0.00 0.00 0.00 -12.70 -17.46

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.70 0.00 0.00 0.00 -17.46

NSE:SENORES vs LLY, JNJ, ABBV: EV-to-FCF Comparison

For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senores Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Senores Pharmaceuticals's EV-to-FCF falls into.


NSE:SENORES
29GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals EV-to-FCF Calculation

Senores Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=65701.577/0
=

Senores Pharmaceuticals's current Enterprise Value is ₹65,702 Mil.
Senores Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
29GF Score

Get the complete analysis for NSE:SENORES

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,417.80
Price